PBE Short Volume
Invesco Biotechnology & Genome ETF (PBE) operates in the Financial Services sector, specifically the Asset Management industry, with a market capitalization near $247.8M, listed on AMEX, carrying a beta of 0.81 to the broader market. The Invesco Biotechnology & Genome ETF (Fund) is based on the Dynamic Biotech & Genome Intellidex Index (Index). public since 2005-06-23.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-05-15
- Short Volume
- 249
- Total Volume
- 1.9K
- Short %
- 13.35%
- 30-Day Avg Short %
- 45.68%
Showing 30 days of FINRA short volume data for Invesco Biotechnology & Genome ETF.
Learn how short volume is reported and how to read the data →
Frequently asked PBE short volume questions
- What is the daily PBE short volume?
- As of May 15, 2026, Invesco Biotechnology & Genome ETF (PBE) short volume is 249 shares against 1.9K total reported volume, or 13.35% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is PBE short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does PBE short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.